Review



mouse junb overexpression plasmid  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    OriGene mouse junb overexpression plasmid
    a Western blot analysis of control and various time periods of VEGFA (40 ng/ml)-treated HRMVECs for the indicated proteins. b The effect of siControl, siPKCθ and siJunB (100 nM) on VEGFA (40 ng/ml)-induced <t>JunB</t> expression at 2 h and PKCθ phosphorylation at 10 min. The blot was sequentially reprobed for PKCθ, JunB, β-tubulin and α-tubulin levels to show the specificity and efficacy of the siRNA on its target and off target molecules. c Upper panel: Western blot analysis of JunB and β-tubulin levels to show the specificity and efficacy of siControl and siJunB (100 nM) in HRMVECs. Bottom panel: The effect of siControl and siJunB on VEGFA (40 ng/ml)-induced HRMVEC migration. d – f All the conditions were same as in ( c ) except that cells were treated with and without VEGFA (40 ng/ml) and DNA synthesis ( d ), sprouting ( e ) or tube formation ( f ) were measured. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as mean ± SD. * p < 0.01 vs vehicle control or siControl; ** p < 0.01 vs siControl + VEGFA. Scale bars in ( e ) and ( f ) are 50 and 200 μm, respectively.
    Mouse Junb Overexpression Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/Junb+(NM_008416)+Mouse+Tagged+ORF+Clone/pmc07206019-44-0-10
    Average 90 stars, based on 1 article reviews
    mouse junb overexpression plasmid - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "PKCθ-JunB axis via upregulation of VEGFR3 expression mediates hypoxia-induced pathological retinal neovascularization"

    Article Title: PKCθ-JunB axis via upregulation of VEGFR3 expression mediates hypoxia-induced pathological retinal neovascularization

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-020-2522-0

    a Western blot analysis of control and various time periods of VEGFA (40 ng/ml)-treated HRMVECs for the indicated proteins. b The effect of siControl, siPKCθ and siJunB (100 nM) on VEGFA (40 ng/ml)-induced JunB expression at 2 h and PKCθ phosphorylation at 10 min. The blot was sequentially reprobed for PKCθ, JunB, β-tubulin and α-tubulin levels to show the specificity and efficacy of the siRNA on its target and off target molecules. c Upper panel: Western blot analysis of JunB and β-tubulin levels to show the specificity and efficacy of siControl and siJunB (100 nM) in HRMVECs. Bottom panel: The effect of siControl and siJunB on VEGFA (40 ng/ml)-induced HRMVEC migration. d – f All the conditions were same as in ( c ) except that cells were treated with and without VEGFA (40 ng/ml) and DNA synthesis ( d ), sprouting ( e ) or tube formation ( f ) were measured. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as mean ± SD. * p < 0.01 vs vehicle control or siControl; ** p < 0.01 vs siControl + VEGFA. Scale bars in ( e ) and ( f ) are 50 and 200 μm, respectively.
    Figure Legend Snippet: a Western blot analysis of control and various time periods of VEGFA (40 ng/ml)-treated HRMVECs for the indicated proteins. b The effect of siControl, siPKCθ and siJunB (100 nM) on VEGFA (40 ng/ml)-induced JunB expression at 2 h and PKCθ phosphorylation at 10 min. The blot was sequentially reprobed for PKCθ, JunB, β-tubulin and α-tubulin levels to show the specificity and efficacy of the siRNA on its target and off target molecules. c Upper panel: Western blot analysis of JunB and β-tubulin levels to show the specificity and efficacy of siControl and siJunB (100 nM) in HRMVECs. Bottom panel: The effect of siControl and siJunB on VEGFA (40 ng/ml)-induced HRMVEC migration. d – f All the conditions were same as in ( c ) except that cells were treated with and without VEGFA (40 ng/ml) and DNA synthesis ( d ), sprouting ( e ) or tube formation ( f ) were measured. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as mean ± SD. * p < 0.01 vs vehicle control or siControl; ** p < 0.01 vs siControl + VEGFA. Scale bars in ( e ) and ( f ) are 50 and 200 μm, respectively.

    Techniques Used: Western Blot, Control, Expressing, Phospho-proteomics, Migration, DNA Synthesis

    a Western blot analysis of retinal extracts of normoxic and 12 h and 24 h of hypoxic WT mice pups for the indicated proteins. b Western blot analysis of retinal extracts of normoxic and 24 h of hypoxic WT and PKCθ −/− mice pups for JunB levels. The blot was subsequently reprobed for PKCθ and β-tubulin levels. c Left panel: Normoxic or hyperoxic JunB flox/flox :Cdh5-Cre ERT2 mice pups at P10 and P11 were injected with 100 μg tamoxifen intraperitoneally, and normoxic and 24 h of hypoxic (P13) pup retinal extracts were prepared and analyzed by western blotting for phospho and total PKCθ, JunB and β-tubulin levels. Right panel: All the conditions were the same as in the left panel except that eyes from normoxic and 72 h of hypoxic pups were enucleated, fixed, sections were made and co-immunostained for CD31 and JunB. d All the conditions are same as in right ( c ) except that eyes were enucleated from normoxic and 120 h of hypoxic pups, fixed, retinas isolated, stained with isolectin B4, flat mounts were made and retinal vascularization and neovascularization were measured. Retinal vascularization is sown in the first column at 2.5× magnification (scale bar 500 μm) and neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). e , f Retinal neovascularization ( e ) and avascular area ( f ) were determined as described in “Materials and Methods”. g Upper panel: All the conditions were the same as in left ( c ) except that sections were co-immunostained for CD31 and Ki67. The extreme right column shows 40× magnification of the areas selected by rectangular boxes in the immediate left column images (scale bars in the far left and far right columns are 200 and 50 μm, respectively). Retinal EC proliferation was measured by counting CD31 and Ki67-positive cells from the inner limiting membrane to the extended region in each section ( n = 6 eyes, 3 sections/eye). Bottom left panel: Quantitative analysis of CD31 and Ki67-positive cells. Bottom right panel: The effect of siControl and siJunB on VEGFA (40 ng/ml)-induced DNA synthesis in MRMVECs. h All the conditions were the same as in ( d ) except that the retinal flat mounts were examined for filopodia at 40× magnification (scale bar, 50 μm). The bar graphs represent quantitative analysis of three blots or 7 retinas. The values are presented as mean ± SD. * p < 0.01 vs normoxia or WT normoxia or siControl; ** p < 0.01 vs WT hypoxia, siControl + hypoxia or siControl + VEGFA.
    Figure Legend Snippet: a Western blot analysis of retinal extracts of normoxic and 12 h and 24 h of hypoxic WT mice pups for the indicated proteins. b Western blot analysis of retinal extracts of normoxic and 24 h of hypoxic WT and PKCθ −/− mice pups for JunB levels. The blot was subsequently reprobed for PKCθ and β-tubulin levels. c Left panel: Normoxic or hyperoxic JunB flox/flox :Cdh5-Cre ERT2 mice pups at P10 and P11 were injected with 100 μg tamoxifen intraperitoneally, and normoxic and 24 h of hypoxic (P13) pup retinal extracts were prepared and analyzed by western blotting for phospho and total PKCθ, JunB and β-tubulin levels. Right panel: All the conditions were the same as in the left panel except that eyes from normoxic and 72 h of hypoxic pups were enucleated, fixed, sections were made and co-immunostained for CD31 and JunB. d All the conditions are same as in right ( c ) except that eyes were enucleated from normoxic and 120 h of hypoxic pups, fixed, retinas isolated, stained with isolectin B4, flat mounts were made and retinal vascularization and neovascularization were measured. Retinal vascularization is sown in the first column at 2.5× magnification (scale bar 500 μm) and neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). e , f Retinal neovascularization ( e ) and avascular area ( f ) were determined as described in “Materials and Methods”. g Upper panel: All the conditions were the same as in left ( c ) except that sections were co-immunostained for CD31 and Ki67. The extreme right column shows 40× magnification of the areas selected by rectangular boxes in the immediate left column images (scale bars in the far left and far right columns are 200 and 50 μm, respectively). Retinal EC proliferation was measured by counting CD31 and Ki67-positive cells from the inner limiting membrane to the extended region in each section ( n = 6 eyes, 3 sections/eye). Bottom left panel: Quantitative analysis of CD31 and Ki67-positive cells. Bottom right panel: The effect of siControl and siJunB on VEGFA (40 ng/ml)-induced DNA synthesis in MRMVECs. h All the conditions were the same as in ( d ) except that the retinal flat mounts were examined for filopodia at 40× magnification (scale bar, 50 μm). The bar graphs represent quantitative analysis of three blots or 7 retinas. The values are presented as mean ± SD. * p < 0.01 vs normoxia or WT normoxia or siControl; ** p < 0.01 vs WT hypoxia, siControl + hypoxia or siControl + VEGFA.

    Techniques Used: Western Blot, Injection, Isolation, Staining, Membrane, DNA Synthesis

    a Western blot analysis of control and the indicated time periods of VEGFA (40 ng/ml)-treated HRMVECs for VEGFR3 and β-tubulin levels. b , c The effect of siControl, siPKCθ and siJunB (100 nM) on VEGFA (40 ng/ml)-induced (2 h) VEGFR3 levels. The blots were sequentially reprobed for PKCθ and β-tubulin levels or JunB and β-tubulin levels to show the specificity and efficacy of siRNA on its target and off target molecules. d Upper panel: Retinal ECs were isolated from WT and PKCθ −/− mice and tested for the effect of VEGFA on PKCθ phosphorylation and JunB and VEGFR3 expression. Lower panel: Retinal ECs from PKCθ −/− mice were transfected with empty vector or JunB expression vector and two days later cell extracts were prepared and analyzed by western blotting for JunB, VEGFR3 and β-tubulin levels. e Upper panel: western blot analysis of VEGFR2, VEGFR3 and β-tubulin levels to show the specificity and efficacy of siControl and siVEGFR3 (100 nM) in HRMVECs. Bottom panel: The effect of siControl, siVEGFR3 and MAZ51 (5 μM) on VEGFA (40 ng/ml)-induced HRMVEC migration. f – h All the conditions were same as in ( e ) except that cells were treated with and without VEGFA (40 ng/ml) and DNA synthesis ( f ), sprouting ( g ) or tube formation ( h ) were measured. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as mean ± SD. * p < 0.01 vs vehicle control or siControl; ** p < 0.01 vs siControl + VEGFA. Scale bars in ( g ) and ( h ) are 50 and 200 μm, respectively.
    Figure Legend Snippet: a Western blot analysis of control and the indicated time periods of VEGFA (40 ng/ml)-treated HRMVECs for VEGFR3 and β-tubulin levels. b , c The effect of siControl, siPKCθ and siJunB (100 nM) on VEGFA (40 ng/ml)-induced (2 h) VEGFR3 levels. The blots were sequentially reprobed for PKCθ and β-tubulin levels or JunB and β-tubulin levels to show the specificity and efficacy of siRNA on its target and off target molecules. d Upper panel: Retinal ECs were isolated from WT and PKCθ −/− mice and tested for the effect of VEGFA on PKCθ phosphorylation and JunB and VEGFR3 expression. Lower panel: Retinal ECs from PKCθ −/− mice were transfected with empty vector or JunB expression vector and two days later cell extracts were prepared and analyzed by western blotting for JunB, VEGFR3 and β-tubulin levels. e Upper panel: western blot analysis of VEGFR2, VEGFR3 and β-tubulin levels to show the specificity and efficacy of siControl and siVEGFR3 (100 nM) in HRMVECs. Bottom panel: The effect of siControl, siVEGFR3 and MAZ51 (5 μM) on VEGFA (40 ng/ml)-induced HRMVEC migration. f – h All the conditions were same as in ( e ) except that cells were treated with and without VEGFA (40 ng/ml) and DNA synthesis ( f ), sprouting ( g ) or tube formation ( h ) were measured. The bar graphs represent quantitative analysis of three independent experiments. The values are presented as mean ± SD. * p < 0.01 vs vehicle control or siControl; ** p < 0.01 vs siControl + VEGFA. Scale bars in ( g ) and ( h ) are 50 and 200 μm, respectively.

    Techniques Used: Western Blot, Control, Isolation, Phospho-proteomics, Expressing, Transfection, Plasmid Preparation, Migration, DNA Synthesis

    a Western blot analysis of retinal extracts of normoxic and the indicated time periods of hypoxic WT mice pups for VEGFR1, VEGFR2, VEGFR3 and β-tubulin levels. b Upper panel: Mice pups were injected intravitreally with 1 μg/0.5 μl/eye of siControl or siVEGFR3 at P11 and P12 and at P13, retinal extracts were prepared and analyzed by western blotting for VEGFR2, VEGFR3 and β-tubulin levels. Bottom panel: All the conditions were the same as in upper panel except that pups were received siRNA at P11, P12 and P13 and at P15, eyes were enucleated, fixed, sections were made and immunostained for CD31 and VEGFR3. c All the conditions are same as in bottom ( b ) except that eyes were enucleated at P17, fixed, retinas were isolated, stained with isolectin B4 and flat mounts were made. Retinal vascularization is shown in the first column at 2.5× magnification (scale bar, 1000 μm). Neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). d , e . Retinal neovascularization ( d ) and avascular area ( e ) were determined as described in “Materials and Methods.” f The effect of siControl and siVEGFR3 on VEGFA (40 ng/ml)-induced DNA synthesis in MRMVECs. g Left panel: All the conditions were the same as in ( c ) except that the retinal flat mounts were examined for filopodia at 40× magnification (scale bar, 50 μm). Right panel: Quantitative analysis of number of filopodia/unit vessel length. h Upper left panel: western blot analysis of normoxic and 24 h of hypoxic retina of WT and PKCθ −/− mice pups for VEGFR3, PKCθ and β-tubulin levels. Bottom left panel: All the conditions were the same as in upper panel except that eyes were enucleated at 3 days of hypoxia (P15), fixed, sections were made and immunostained for CD31 and VEGFR3. Upper and bottom right panels: Quantitative analysis of VEGFR3 levels and CD31 and VEGFR3-positive cells, respectively. i Upper left panel: Normoxic or hyperoxic JunB flox/flox :Cdh5-Cre ERT2 mice pups at P10 and P11 were injected with 100 μg tamoxifen intraperitoneally, and RNA was isolated from normoxic and 24 h of hypoxic (P13) pup retinas and analyzed by RT-PCR for VEGFR3 and α-actin mRNA levels. Upper right panel: All the conditions were the same as in the left panel except that retinal extracts were prepared and analyzed for western blotting for VEGFR3, JunB and β-tubulin levels. Lower panel: All the conditions were the same as in the upper panels except that eyes were enucleated, fixed, sections were made and co-immunostained for CD31 and VEGFR3. The bar graphs represent quantitative analysis of three blots or 7 retinas. The values are presented as mean ± SD. * p < 0.01 vs normoxia or WT + normoxia or siControl + normoxia; ** p < 0.01 vs WT + hypoxia or siControl + hypoxia.
    Figure Legend Snippet: a Western blot analysis of retinal extracts of normoxic and the indicated time periods of hypoxic WT mice pups for VEGFR1, VEGFR2, VEGFR3 and β-tubulin levels. b Upper panel: Mice pups were injected intravitreally with 1 μg/0.5 μl/eye of siControl or siVEGFR3 at P11 and P12 and at P13, retinal extracts were prepared and analyzed by western blotting for VEGFR2, VEGFR3 and β-tubulin levels. Bottom panel: All the conditions were the same as in upper panel except that pups were received siRNA at P11, P12 and P13 and at P15, eyes were enucleated, fixed, sections were made and immunostained for CD31 and VEGFR3. c All the conditions are same as in bottom ( b ) except that eyes were enucleated at P17, fixed, retinas were isolated, stained with isolectin B4 and flat mounts were made. Retinal vascularization is shown in the first column at 2.5× magnification (scale bar, 1000 μm). Neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). d , e . Retinal neovascularization ( d ) and avascular area ( e ) were determined as described in “Materials and Methods.” f The effect of siControl and siVEGFR3 on VEGFA (40 ng/ml)-induced DNA synthesis in MRMVECs. g Left panel: All the conditions were the same as in ( c ) except that the retinal flat mounts were examined for filopodia at 40× magnification (scale bar, 50 μm). Right panel: Quantitative analysis of number of filopodia/unit vessel length. h Upper left panel: western blot analysis of normoxic and 24 h of hypoxic retina of WT and PKCθ −/− mice pups for VEGFR3, PKCθ and β-tubulin levels. Bottom left panel: All the conditions were the same as in upper panel except that eyes were enucleated at 3 days of hypoxia (P15), fixed, sections were made and immunostained for CD31 and VEGFR3. Upper and bottom right panels: Quantitative analysis of VEGFR3 levels and CD31 and VEGFR3-positive cells, respectively. i Upper left panel: Normoxic or hyperoxic JunB flox/flox :Cdh5-Cre ERT2 mice pups at P10 and P11 were injected with 100 μg tamoxifen intraperitoneally, and RNA was isolated from normoxic and 24 h of hypoxic (P13) pup retinas and analyzed by RT-PCR for VEGFR3 and α-actin mRNA levels. Upper right panel: All the conditions were the same as in the left panel except that retinal extracts were prepared and analyzed for western blotting for VEGFR3, JunB and β-tubulin levels. Lower panel: All the conditions were the same as in the upper panels except that eyes were enucleated, fixed, sections were made and co-immunostained for CD31 and VEGFR3. The bar graphs represent quantitative analysis of three blots or 7 retinas. The values are presented as mean ± SD. * p < 0.01 vs normoxia or WT + normoxia or siControl + normoxia; ** p < 0.01 vs WT + hypoxia or siControl + hypoxia.

    Techniques Used: Western Blot, Injection, Isolation, Staining, DNA Synthesis, Reverse Transcription Polymerase Chain Reaction

    a Upper panel: Equal amount of protein from control and the indicated time periods of VEGFA-treated HRMVECs were analyzed for phospho and total VEGFR1, 2 and 3 levels. Lower panel: The cell extracts were analyzed for VEGFR2 and VEGFR3 complex formation. b HRMVECs were transfected with siControl or siVEGFR2 (100 nM), quiesced, treated with and without VEGFA (40 ng/ml) for 10 min (for pPKCθ) or 120 min (for JunB and VEGFR3) and cell extracts were prepared and analyzed by western blotting for the indicated proteins. c Retinas from normoxic and 24 h (i.e., at P13) of hypoxic WT mice pups that received siControl or siVEGFR2 (1 μg/0.5 μl/eye) by intravitreal injections at P10 and P11 were isolated, extracts were prepared and analyzed by western blotting for the indicated proteins. d Eyes from normoxic and 72 h (i.e., at P15) of hypoxic WT mice pups that received siControl or siVEGFR2 (1 μg/0.5 μl/eye) by intravitreal injections at P11, P12 and P13 were enucleated, fixed, sections were made and coimmunostained for CD31 and VEGFR2 (left panel) and CD31 and VEGFR3 (right panel). e Eyes from normoxic and 24 h (i.e., at P13) of hypoxic WT mice pups that were injected intravitreally with vehicle or 0.05 μg/0.5 μl/eye of soluble VEGFR2 at P11 and P12 were enucleated, retinas were isolated, protein extracts were prepared and analyzed by western blotting for the indicated proteins using their specific antibodies. f Eyes from normoxic and 24 h of hypoxic mice pups that were injected intravitreally with siControl or siVEGFR2 (0.5 μg/0.5 μl/eye) at P11 and P12 were enucleated, retinas were isolated, protein extracts were prepared and analyzed by western blotting for VEGFR3 levels using its specific antibodies and the blot was normalized for β-tubulin. g All the conditions were the same as in ( d ) except that sections were coimmunostained for CD31 and Ki67. The bar graph shows quantification of proliferating ECs per section. h All the conditions were the same as in ( d ) except that eyes were enucleated at P17, fixed, retinas were isolated, stained with isolectin B4, flat mounts were made and examined for filopodia at 40× magnification (scale bar, 50 μm). Bar graph shows quantification of the number of filopodia/unit vessel length. i All the conditions were the same as in ( h ) except that the flat mounts were examined for retinal vascularization. Retinal vascularization is shown in the first column at 2.5× magnification (scale bar, 500 μm). Neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). j , k Retinal neovascularization ( j ) and avascular area ( k ) were determined as described in “Materials and Methods.” The values are presented as mean ± SD. * p < 0.01 vs normoxia; ** p < 0.01 vs siControl + hypoxia.
    Figure Legend Snippet: a Upper panel: Equal amount of protein from control and the indicated time periods of VEGFA-treated HRMVECs were analyzed for phospho and total VEGFR1, 2 and 3 levels. Lower panel: The cell extracts were analyzed for VEGFR2 and VEGFR3 complex formation. b HRMVECs were transfected with siControl or siVEGFR2 (100 nM), quiesced, treated with and without VEGFA (40 ng/ml) for 10 min (for pPKCθ) or 120 min (for JunB and VEGFR3) and cell extracts were prepared and analyzed by western blotting for the indicated proteins. c Retinas from normoxic and 24 h (i.e., at P13) of hypoxic WT mice pups that received siControl or siVEGFR2 (1 μg/0.5 μl/eye) by intravitreal injections at P10 and P11 were isolated, extracts were prepared and analyzed by western blotting for the indicated proteins. d Eyes from normoxic and 72 h (i.e., at P15) of hypoxic WT mice pups that received siControl or siVEGFR2 (1 μg/0.5 μl/eye) by intravitreal injections at P11, P12 and P13 were enucleated, fixed, sections were made and coimmunostained for CD31 and VEGFR2 (left panel) and CD31 and VEGFR3 (right panel). e Eyes from normoxic and 24 h (i.e., at P13) of hypoxic WT mice pups that were injected intravitreally with vehicle or 0.05 μg/0.5 μl/eye of soluble VEGFR2 at P11 and P12 were enucleated, retinas were isolated, protein extracts were prepared and analyzed by western blotting for the indicated proteins using their specific antibodies. f Eyes from normoxic and 24 h of hypoxic mice pups that were injected intravitreally with siControl or siVEGFR2 (0.5 μg/0.5 μl/eye) at P11 and P12 were enucleated, retinas were isolated, protein extracts were prepared and analyzed by western blotting for VEGFR3 levels using its specific antibodies and the blot was normalized for β-tubulin. g All the conditions were the same as in ( d ) except that sections were coimmunostained for CD31 and Ki67. The bar graph shows quantification of proliferating ECs per section. h All the conditions were the same as in ( d ) except that eyes were enucleated at P17, fixed, retinas were isolated, stained with isolectin B4, flat mounts were made and examined for filopodia at 40× magnification (scale bar, 50 μm). Bar graph shows quantification of the number of filopodia/unit vessel length. i All the conditions were the same as in ( h ) except that the flat mounts were examined for retinal vascularization. Retinal vascularization is shown in the first column at 2.5× magnification (scale bar, 500 μm). Neovascularization is highlighted in red in the second column. The third column shows the selected rectangular areas of the images in the first column at 10× magnification (scale bar, 200 μm). j , k Retinal neovascularization ( j ) and avascular area ( k ) were determined as described in “Materials and Methods.” The values are presented as mean ± SD. * p < 0.01 vs normoxia; ** p < 0.01 vs siControl + hypoxia.

    Techniques Used: Control, Transfection, Western Blot, Isolation, Injection, Staining

    Related Articles

    Over Expression:

    Article Title: PKCθ-JunB axis via upregulation of VEGFR3 expression mediates hypoxia-induced pathological retinal neovascularization
    Article Snippet: Isolectin B4-594 (I21413), cell tracker green (C7025), goat anti-rabbit IgG-AlexaFluor 488 (A11034), goat anti-rat IgG-AlexaFluor 568 (A11077), goat anti-rat IgG-AlexaFluor 350 (A21093), Hoechst 3342, Prolong Gold antifade reagent were bought from Molecular Probes (Eugene, OR). .. Mouse JunB overexpression plasmid (Cat. No. MR336772) was obtained from Origene Technologies Inc. (Rockville, MD). .. JunB flox/flox mice (stock # 012369) and PKCθ −/− mice (stock # 005711) were purchased from Jackson Laboratories, Bar Harbor, ME.

    Plasmid Preparation:

    Article Title: PKCθ-JunB axis via upregulation of VEGFR3 expression mediates hypoxia-induced pathological retinal neovascularization
    Article Snippet: Isolectin B4-594 (I21413), cell tracker green (C7025), goat anti-rabbit IgG-AlexaFluor 488 (A11034), goat anti-rat IgG-AlexaFluor 568 (A11077), goat anti-rat IgG-AlexaFluor 350 (A21093), Hoechst 3342, Prolong Gold antifade reagent were bought from Molecular Probes (Eugene, OR). .. Mouse JunB overexpression plasmid (Cat. No. MR336772) was obtained from Origene Technologies Inc. (Rockville, MD). .. JunB flox/flox mice (stock # 012369) and PKCθ −/− mice (stock # 005711) were purchased from Jackson Laboratories, Bar Harbor, ME.



    Similar Products

    93
    NSJ Bioreagents junb antibody
    Junb Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/JUNB+Antibody/custom%40v9262%4041546063
    Average 93 stars, based on 1 article reviews
    junb antibody - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Abmart Inc antibodies against junb
    hdWGCNA analysis of gene co-expression modules and functional enrichment in Müller glial subpopulations cluster 0 and 1 in STZ and Ctrl groups. (A) Soft power threshold selection for the weighted network construction in the hierarchical clustering analysis of Müller glia subpopulations. The figure showed the correlation between the soft power threshold and model fit, as well as mean connectivity, median connectivity and max connectivity, with the optimal threshold indicated for constructing the network. The selected <t>power</t> <t>(β</t> = 5) represents the minimal value satisfying the scale-free topology criterion while preserving sufficient network connectivity for module detection. (B) Hierarchical clustering dendrogram of Müller glial subpopulations based on gene expression profiles. The tree showed clustering of the different gene modules identified in the analysis, with modules labeled Müller-M1 to Müller-M6. Each module represents a set of co-expressed genes associated with specific biological functions in Müller glial subpopulation. (C) Module feature plots showing the expression patterns of each module (M1-M6) within Müller cell subpopulations. For each module, cells were colored by module expression level (low to high), illustrating the distribution of module activity across Müller cell subpopulations. (D) The module membership (kME) for all genes was calculated, and the top-ranked 10 genes within each module were visualized using PlotKMEs. (E) Dot plots respectively showing the expression of distinct gene co-expression modules in Müller glial cell subpopulation and the module expression within subpopulations under different conditions. (F) Co-expression network comprising the top five hub genes from each co-expression module. (G) Network graphs showing hub-gene networks constructed from the top 25 core genes of modules 1 and 6; the inner ring denotes the top 10 hub genes and the outer ring denotes the remaining 15. (H, I) Bar charts showing functional enrichment terms for the top 100 genes from modules 1 and 6. (J) PPI network analysis of genes in Module 6, showing the top 10 hub genes selected based on connectivity scores. (K) Western blot validation of <t>JUNB</t> protein expression levels in the Ctrl and STZ groups (N = 3), confirming differential expression. * indicates p < 0.05.
    Antibodies Against Junb, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/anti+junb/pmc13168181-81-23-26
    Average 86 stars, based on 1 article reviews
    antibodies against junb - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    89
    Thermo Fisher gene exp junb mm04243546 s1
    hdWGCNA analysis of gene co-expression modules and functional enrichment in Müller glial subpopulations cluster 0 and 1 in STZ and Ctrl groups. (A) Soft power threshold selection for the weighted network construction in the hierarchical clustering analysis of Müller glia subpopulations. The figure showed the correlation between the soft power threshold and model fit, as well as mean connectivity, median connectivity and max connectivity, with the optimal threshold indicated for constructing the network. The selected <t>power</t> <t>(β</t> = 5) represents the minimal value satisfying the scale-free topology criterion while preserving sufficient network connectivity for module detection. (B) Hierarchical clustering dendrogram of Müller glial subpopulations based on gene expression profiles. The tree showed clustering of the different gene modules identified in the analysis, with modules labeled Müller-M1 to Müller-M6. Each module represents a set of co-expressed genes associated with specific biological functions in Müller glial subpopulation. (C) Module feature plots showing the expression patterns of each module (M1-M6) within Müller cell subpopulations. For each module, cells were colored by module expression level (low to high), illustrating the distribution of module activity across Müller cell subpopulations. (D) The module membership (kME) for all genes was calculated, and the top-ranked 10 genes within each module were visualized using PlotKMEs. (E) Dot plots respectively showing the expression of distinct gene co-expression modules in Müller glial cell subpopulation and the module expression within subpopulations under different conditions. (F) Co-expression network comprising the top five hub genes from each co-expression module. (G) Network graphs showing hub-gene networks constructed from the top 25 core genes of modules 1 and 6; the inner ring denotes the top 10 hub genes and the outer ring denotes the remaining 15. (H, I) Bar charts showing functional enrichment terms for the top 100 genes from modules 1 and 6. (J) PPI network analysis of genes in Module 6, showing the top 10 hub genes selected based on connectivity scores. (K) Western blot validation of <t>JUNB</t> protein expression levels in the Ctrl and STZ groups (N = 3), confirming differential expression. * indicates p < 0.05.
    Gene Exp Junb Mm04243546 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/Gene+Exp%2E+Junb%2C+Mm04243546_s1/pm42015926-80-15-3
    Average 89 stars, based on 1 article reviews
    gene exp junb mm04243546 s1 - by Bioz Stars, 2026-11
    89/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc junb
    (A) Log2(fold change) of the four guides targeting <t>JunB</t> (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). <t>(D)</t> <t>JunD</t> sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005
    Junb, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/bio_rxiv__64898__2026__03__31__715635-225-10-11
    Average 86 stars, based on 1 article reviews
    junb - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti junb
    (A) Log2(fold change) of the four guides targeting <t>JunB</t> (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). <t>(D)</t> <t>JunD</t> sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005
    Anti Junb, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/JunB+Rabbit+mAb/pm41930557-74-47-50
    Average 95 stars, based on 1 article reviews
    anti junb - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Novus Biologicals mfluor violet 450 se conjugated anti c jun
    (A) Log2(fold change) of the four guides targeting <t>JunB</t> (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). <t>(D)</t> <t>JunD</t> sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005
    Mfluor Violet 450 Se Conjugated Anti C Jun, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/JunB%2FAP-1+Antibody+(PCRP-JUNB-3G2)+%5BmFluor+Violet+450+SE%5D/pmc12892447-175-27-36
    Average 94 stars, based on 1 article reviews
    mfluor violet 450 se conjugated anti c jun - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals anti junb ap 1
    (A) Log2(fold change) of the four guides targeting <t>JunB</t> (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). <t>(D)</t> <t>JunD</t> sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005
    Anti Junb Ap 1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/junb/JunB%2FAP-1+Antibody+(PCRP-JUNB-3G2)+%5BFITC%5D/pmc12892447-175-20-23
    Average 94 stars, based on 1 article reviews
    anti junb ap 1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    hdWGCNA analysis of gene co-expression modules and functional enrichment in Müller glial subpopulations cluster 0 and 1 in STZ and Ctrl groups. (A) Soft power threshold selection for the weighted network construction in the hierarchical clustering analysis of Müller glia subpopulations. The figure showed the correlation between the soft power threshold and model fit, as well as mean connectivity, median connectivity and max connectivity, with the optimal threshold indicated for constructing the network. The selected power (β = 5) represents the minimal value satisfying the scale-free topology criterion while preserving sufficient network connectivity for module detection. (B) Hierarchical clustering dendrogram of Müller glial subpopulations based on gene expression profiles. The tree showed clustering of the different gene modules identified in the analysis, with modules labeled Müller-M1 to Müller-M6. Each module represents a set of co-expressed genes associated with specific biological functions in Müller glial subpopulation. (C) Module feature plots showing the expression patterns of each module (M1-M6) within Müller cell subpopulations. For each module, cells were colored by module expression level (low to high), illustrating the distribution of module activity across Müller cell subpopulations. (D) The module membership (kME) for all genes was calculated, and the top-ranked 10 genes within each module were visualized using PlotKMEs. (E) Dot plots respectively showing the expression of distinct gene co-expression modules in Müller glial cell subpopulation and the module expression within subpopulations under different conditions. (F) Co-expression network comprising the top five hub genes from each co-expression module. (G) Network graphs showing hub-gene networks constructed from the top 25 core genes of modules 1 and 6; the inner ring denotes the top 10 hub genes and the outer ring denotes the remaining 15. (H, I) Bar charts showing functional enrichment terms for the top 100 genes from modules 1 and 6. (J) PPI network analysis of genes in Module 6, showing the top 10 hub genes selected based on connectivity scores. (K) Western blot validation of JUNB protein expression levels in the Ctrl and STZ groups (N = 3), confirming differential expression. * indicates p < 0.05.

    Journal: Frontiers in Immunology

    Article Title: Single cell transcriptomic analysis reveals pathogenic cell heterogeneity and candidate inflammatory-associated markers in STZ-induced diabetic mouse retina

    doi: 10.3389/fimmu.2026.1827122

    Figure Lengend Snippet: hdWGCNA analysis of gene co-expression modules and functional enrichment in Müller glial subpopulations cluster 0 and 1 in STZ and Ctrl groups. (A) Soft power threshold selection for the weighted network construction in the hierarchical clustering analysis of Müller glia subpopulations. The figure showed the correlation between the soft power threshold and model fit, as well as mean connectivity, median connectivity and max connectivity, with the optimal threshold indicated for constructing the network. The selected power (β = 5) represents the minimal value satisfying the scale-free topology criterion while preserving sufficient network connectivity for module detection. (B) Hierarchical clustering dendrogram of Müller glial subpopulations based on gene expression profiles. The tree showed clustering of the different gene modules identified in the analysis, with modules labeled Müller-M1 to Müller-M6. Each module represents a set of co-expressed genes associated with specific biological functions in Müller glial subpopulation. (C) Module feature plots showing the expression patterns of each module (M1-M6) within Müller cell subpopulations. For each module, cells were colored by module expression level (low to high), illustrating the distribution of module activity across Müller cell subpopulations. (D) The module membership (kME) for all genes was calculated, and the top-ranked 10 genes within each module were visualized using PlotKMEs. (E) Dot plots respectively showing the expression of distinct gene co-expression modules in Müller glial cell subpopulation and the module expression within subpopulations under different conditions. (F) Co-expression network comprising the top five hub genes from each co-expression module. (G) Network graphs showing hub-gene networks constructed from the top 25 core genes of modules 1 and 6; the inner ring denotes the top 10 hub genes and the outer ring denotes the remaining 15. (H, I) Bar charts showing functional enrichment terms for the top 100 genes from modules 1 and 6. (J) PPI network analysis of genes in Module 6, showing the top 10 hub genes selected based on connectivity scores. (K) Western blot validation of JUNB protein expression levels in the Ctrl and STZ groups (N = 3), confirming differential expression. * indicates p < 0.05.

    Article Snippet: Membranes were blocked with 5% nonfat milk in TBST for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against JUNB (Abmart, T55894 , 1:2000), CEBPB (Abmart, T55276 , 1:2000), and β-actin (Affinity, AF7018, 1:20000).

    Techniques: Expressing, Functional Assay, Selection, Preserving, Gene Expression, Labeling, Activity Assay, Construct, Western Blot, Biomarker Discovery, Quantitative Proteomics

    (A) Log2(fold change) of the four guides targeting JunB (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (D) JunD sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Journal: bioRxiv

    Article Title: CRISPR Screens Reveal Epstein-Barr Virus-activated JunB as a Key Lymphoblastoid B cell Dependency Factor that Represses Cyclin Dependent Kinase Inhibitor P18INK4c

    doi: 10.64898/2026.03.31.715635

    Figure Lengend Snippet: (A) Log2(fold change) of the four guides targeting JunB (red) compared to the distribution of all sgRNA guides from the GM12878 and P3HR-1 Avana dropout screen. Fold change was calculated comparing abundance of sgRNA day 21 post selection versus input. (B) JunB sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunB sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (C) c-Jun sgRNA abundances in Brunello and Avana dropout screens. Log 2 c-Jun sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (D) JunD sgRNA abundances in Brunello and Avana dropout screens. Log 2 JunD sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (E) JunB dependency across CRISPR DepMap lymphoid cell lines ( DepMap.org ). Gene dependency scores were calculated by comparing JunB sgRNA abundance in individual lymphoid cell lines 21 days post lentivirus library transduction and selection in comparison to input library abundance. Each circle indicates an individual lymphoid cell line. Circle size represents Log JunB reads from RNA-seq analysis (DepMap, Broad, DepMap Public 25Q3 (2025)) Green circles versus clear circles indicate DepMap Burkitt versus non-Burkitt lymphoid cell lines, respectively. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Article Snippet: Antibodies against the following proteins were used in this study: JunB (Cell Signaling Technology, #3753), c-Jun (Cell Signaling Biotechnology, #9165), JunD (Cell Signaling Biotechnology, #5000), β-Actin (Biolegend, #664802), LMP1 (Abcam, ab78113), LMP2A (Abcam, ab59028), EBNA2 PE2 (a gift from Fred Wang), DDX1 (Bethyl, A300-521A-M), Myc (Santa Cruz Biotechnology, SC-40), p100/p52 (EMD Millipore, 05-361), TRAF1 (Cell Signaling Biotechnology, #4715S), HA tag antibody (Cell Signaling Technology, # 3724), BIM (Cell Signaling Biotechnology, #2933), CCND2 (Proteintech, 10934-1-AP), EBNA1 (a gift from Jaap Middeldorp), and EBNA3C A10 (hybridoma from Martin Rowe’s group[ ]).

    Techniques: Selection, Sequencing, CRISPR, Transduction, Comparison, RNA Sequencing

    (A) Validation of JunB CRISPR-Cas9 knockout in MUTU I and GM15892 cells. Immunoblot was performed on WCL from Cas9+ MUTU I and GM15892 cells transduced with control or JunB sgRNA seven days post-selection using indicated antibodies. (B) Mean ± SD live cell numbers of Cas9+ MUTU I or GM11830 cells expressing control or JunB targeting single guide RNAs (sgRNA) from n=3 replicates. Cells transduced with lentiviruses expressing the indicated sgRNAs were puromycin selected. Cell numbers two days following puromycin selection (defined as day 0 of the graph) were set to 1. Live cell numbers were quantitated by CellTiter-Glo assay (C) Investigation of impact of JunB on other Jun AP-1 transcription factors. Immunoblot analysis of WCL from Cas9+ GM12878 cells transduced with control or JunB sgRNAs, ten days post selection, with indicated antibodies. Densitometry ratios of JunB and JunD to β-Actin is shown. (D) Investigation of combinatorial impact of JunB and JunD on LCL growth. (Left) Mean ± SD live cell numbers of Cas9+ GM12878 cells expressing control, JunD, JunB, or JunB+JunD targeting single guide RNAs (sgRNA) from n=3 replicates. Cells transduced with lentiviruses expressing control or JunD sgRNA were Zeocin selected two days post transduction. After one week, cells were then transduced with a separate control or JunB sgRNA. Cell numbers two days following puromycin selection (defined as day 0 of the graph) were set to 1. Live cell numbers were quantitated by CellTiter-Glo assay. (Right) Immunoblot validation of JunB and JunD knockouts. WCL of GM12878 cells transduced with both zeocin and puromycin sgRNAs was extracted two days following puromycin selection and immunoblot was performed using indicate antibodies. (E) PI cell cycle stainin of GM12878 cells transduced with JunB sgRNA. Representative FACS cell cycle plots from n=3 replicates of GM12878 cells analyzed ten days post selection. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Journal: bioRxiv

    Article Title: CRISPR Screens Reveal Epstein-Barr Virus-activated JunB as a Key Lymphoblastoid B cell Dependency Factor that Represses Cyclin Dependent Kinase Inhibitor P18INK4c

    doi: 10.64898/2026.03.31.715635

    Figure Lengend Snippet: (A) Validation of JunB CRISPR-Cas9 knockout in MUTU I and GM15892 cells. Immunoblot was performed on WCL from Cas9+ MUTU I and GM15892 cells transduced with control or JunB sgRNA seven days post-selection using indicated antibodies. (B) Mean ± SD live cell numbers of Cas9+ MUTU I or GM11830 cells expressing control or JunB targeting single guide RNAs (sgRNA) from n=3 replicates. Cells transduced with lentiviruses expressing the indicated sgRNAs were puromycin selected. Cell numbers two days following puromycin selection (defined as day 0 of the graph) were set to 1. Live cell numbers were quantitated by CellTiter-Glo assay (C) Investigation of impact of JunB on other Jun AP-1 transcription factors. Immunoblot analysis of WCL from Cas9+ GM12878 cells transduced with control or JunB sgRNAs, ten days post selection, with indicated antibodies. Densitometry ratios of JunB and JunD to β-Actin is shown. (D) Investigation of combinatorial impact of JunB and JunD on LCL growth. (Left) Mean ± SD live cell numbers of Cas9+ GM12878 cells expressing control, JunD, JunB, or JunB+JunD targeting single guide RNAs (sgRNA) from n=3 replicates. Cells transduced with lentiviruses expressing control or JunD sgRNA were Zeocin selected two days post transduction. After one week, cells were then transduced with a separate control or JunB sgRNA. Cell numbers two days following puromycin selection (defined as day 0 of the graph) were set to 1. Live cell numbers were quantitated by CellTiter-Glo assay. (Right) Immunoblot validation of JunB and JunD knockouts. WCL of GM12878 cells transduced with both zeocin and puromycin sgRNAs was extracted two days following puromycin selection and immunoblot was performed using indicate antibodies. (E) PI cell cycle stainin of GM12878 cells transduced with JunB sgRNA. Representative FACS cell cycle plots from n=3 replicates of GM12878 cells analyzed ten days post selection. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Article Snippet: Antibodies against the following proteins were used in this study: JunB (Cell Signaling Technology, #3753), c-Jun (Cell Signaling Biotechnology, #9165), JunD (Cell Signaling Biotechnology, #5000), β-Actin (Biolegend, #664802), LMP1 (Abcam, ab78113), LMP2A (Abcam, ab59028), EBNA2 PE2 (a gift from Fred Wang), DDX1 (Bethyl, A300-521A-M), Myc (Santa Cruz Biotechnology, SC-40), p100/p52 (EMD Millipore, 05-361), TRAF1 (Cell Signaling Biotechnology, #4715S), HA tag antibody (Cell Signaling Technology, # 3724), BIM (Cell Signaling Biotechnology, #2933), CCND2 (Proteintech, 10934-1-AP), EBNA1 (a gift from Jaap Middeldorp), and EBNA3C A10 (hybridoma from Martin Rowe’s group[ ]).

    Techniques: Biomarker Discovery, CRISPR, Knock-Out, Western Blot, Transduction, Control, Selection, Expressing, Glo Assay

    (A) CCND2 sgRNA abundances in Brunello P3HR-1 and GM12878 dropout screens. Log 2 CCND2 sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (B) CCND2 transcript levels during EBV-mediated B cell transformation. RNAseq was performed on primary B cells infected with B95-8 virus on indicated days post infection (dpi). Normalized reads for CCND2 are shown. (C) Immunoblot analysis of CCND2 levels in response to LMP1 expression. Daudi Burkitt cells harboring selectively inducible WT or transformation effector site (TES) mutant LMP1 cassettes were mock induced or treated with 250 ng / mL doxycycline for 24 hours. Cells were then harvested and lysates analyzed via immunoblot with indicated antibodies. (D) Effect of JunB knockout on CCND2 levels. Cas9+ P3HR-1, Jijoye, or GM12878 cells expressing control or JunB sgRNAs. Seven days post selection, WCL was extracted from cells and immunoblot performed using indicated antibodies. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Journal: bioRxiv

    Article Title: CRISPR Screens Reveal Epstein-Barr Virus-activated JunB as a Key Lymphoblastoid B cell Dependency Factor that Represses Cyclin Dependent Kinase Inhibitor P18INK4c

    doi: 10.64898/2026.03.31.715635

    Figure Lengend Snippet: (A) CCND2 sgRNA abundances in Brunello P3HR-1 and GM12878 dropout screens. Log 2 CCND2 sgRNA abundances from GM12878 (red) and P3HR-1 (blue) cells 21 days post library selection were determined via deep sequencing and compared to input library sgRNA abundance (green). (B) CCND2 transcript levels during EBV-mediated B cell transformation. RNAseq was performed on primary B cells infected with B95-8 virus on indicated days post infection (dpi). Normalized reads for CCND2 are shown. (C) Immunoblot analysis of CCND2 levels in response to LMP1 expression. Daudi Burkitt cells harboring selectively inducible WT or transformation effector site (TES) mutant LMP1 cassettes were mock induced or treated with 250 ng / mL doxycycline for 24 hours. Cells were then harvested and lysates analyzed via immunoblot with indicated antibodies. (D) Effect of JunB knockout on CCND2 levels. Cas9+ P3HR-1, Jijoye, or GM12878 cells expressing control or JunB sgRNAs. Seven days post selection, WCL was extracted from cells and immunoblot performed using indicated antibodies. P-values were determined by one-sided Fisher’s exact test. * p<0.05, **p<0.005, ***p<0.0005

    Article Snippet: Antibodies against the following proteins were used in this study: JunB (Cell Signaling Technology, #3753), c-Jun (Cell Signaling Biotechnology, #9165), JunD (Cell Signaling Biotechnology, #5000), β-Actin (Biolegend, #664802), LMP1 (Abcam, ab78113), LMP2A (Abcam, ab59028), EBNA2 PE2 (a gift from Fred Wang), DDX1 (Bethyl, A300-521A-M), Myc (Santa Cruz Biotechnology, SC-40), p100/p52 (EMD Millipore, 05-361), TRAF1 (Cell Signaling Biotechnology, #4715S), HA tag antibody (Cell Signaling Technology, # 3724), BIM (Cell Signaling Biotechnology, #2933), CCND2 (Proteintech, 10934-1-AP), EBNA1 (a gift from Jaap Middeldorp), and EBNA3C A10 (hybridoma from Martin Rowe’s group[ ]).

    Techniques: Selection, Sequencing, Transformation Assay, RNA sequencing, Infection, Virus, Western Blot, Expressing, Mutagenesis, Knock-Out, Control